Biotech and Pharmaceuticals
Eli Lilly CEO says company can help ‘respond’ to national security concerns around essential drugs as tariffs loom
CEO of Eli Lilly and Company David Ricks speaks at the Economic Club of New York on March 12, 2024 in New York City. Spencer Platt | Getty Images Eli Lilly CEO Dave Ricks on Thursday said the drugmaker can help “respond” to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom. The […]
Read More
CVS tops estimates, hikes guidance as insurance business shows some improvement
CVS Pharmacy logo is seen in Washington DC, United States on July 9, 2024. Jakub Porzycki | Nurphoto | Getty Images CVS Health on Thursday reported first-quarter earnings and revenue that topped estimates and hiked its guidance, as its troubled insurance business showed some improvement during the period. The company now expects full-year adjusted earnings […]
Read More
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom
Jgi/jamie Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Tariff threats — and efforts to get into President Donald Trump’s good graces — are fueling a new wave […]
Read More
RFK Jr. is gutting minority health offices across HHS that are key to reducing health disparities
Employees of the Department of Health and Human Services (HHS) queue outside the Mary E. Switzer Memorial Building, after it was reported that the Trump administration fired staff at the Centers for Disease Control and Prevention and at the Food and Drug Administration, as it embarked on its plan to cut 10,000 jobs at HHS, […]
Read More
GLP-1s can help employers lower medical costs in 2 years, new study finds
Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images The growing demand for diabetes and weight loss drugs like Mounjaro, Ozempic and Wegovy has helped fuel higher health costs for large employers. For many, the big question is whether the pricy medications known as GLP-1s will pay off by improving […]
Read More
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | Reuters Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and […]
Read More
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 30%
The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images Novo Nordisk on Tuesday said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and […]
Read More
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
The Pfizer logo is seen outside the pharmaceutical company’s manufacturing plant, in Newbridge, Ireland February 10, 2025. Clodagh Kilcoyne | Reuters Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company’s sales fell, largely due to dwindling revenue for its antiviral Covid pill Paxlovid. The company previously […]
Read More
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk scored a huge legal victory that […]
Read More
Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise
Bristol Myers Squibb ‘s earnings beat and rosy outlook Thursday did not resolve lingering issues for the stock. But it was enough, for now. Revenue in the first quarter, which ended March 31, dipped 6% to $11.2 billion but topped estimates of $10.7 billion, according to LSEG. Adjusted earnings per share of $1.80 beat expectations […]
Read More